Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Andrea Sabens Sells 386 Shares

Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) CAO Andrea Sabens sold 386 shares of the stock in a transaction that occurred on Wednesday, June 15th. The stock was sold at an average price of $62.87, for a total value of $24,267.82. Following the sale, the chief accounting officer now directly owns 64,441 shares of the company’s stock, valued at $4,051,405.67. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Shares of NASDAQ LNTH traded up $1.18 during trading hours on Friday, hitting $60.72. The company had a trading volume of 1,838,969 shares, compared to its average volume of 1,092,121. The stock has a market capitalization of $4.17 billion, a P/E ratio of -106.42, a price-to-earnings-growth ratio of 0.68 and a beta of 0.75. The company has a quick ratio of 1.64, a current ratio of 1.83 and a debt-to-equity ratio of 0.31. Lantheus Holdings, Inc. has a 1-year low of $22.20 and a 1-year high of $73.78. The firm’s 50 day moving average is $63.64 and its 200-day moving average is $45.56.

Lantheus (NASDAQ:LNTHGet Rating) last released its quarterly earnings data on Friday, April 29th. The medical equipment provider reported $0.97 EPS for the quarter, beating the consensus estimate of $0.46 by $0.51. The company had revenue of $208.90 million during the quarter, compared to the consensus estimate of $165.30 million. Lantheus had a positive return on equity of 19.83% and a negative net margin of 6.89%. The firm’s revenue for the quarter was up 125.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.05 EPS. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 2.79 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its holdings in Lantheus by 79.5% during the 2nd quarter. Wells Fargo & Company MN now owns 63,953 shares of the medical equipment provider’s stock valued at $1,767,000 after purchasing an additional 28,329 shares during the last quarter. Morgan Stanley lifted its holdings in Lantheus by 49.0% during the 2nd quarter. Morgan Stanley now owns 255,027 shares of the medical equipment provider’s stock valued at $7,050,000 after purchasing an additional 83,817 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Lantheus during the 3rd quarter valued at $697,000. Dimensional Fund Advisors LP lifted its holdings in Lantheus by 6.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,694,720 shares of the medical equipment provider’s stock valued at $43,521,000 after purchasing an additional 102,689 shares during the last quarter. Finally, AXA S.A. acquired a new stake in Lantheus during the 3rd quarter valued at $516,000. 97.14% of the stock is owned by institutional investors.

A number of analysts recently issued reports on the company. B. Riley assumed coverage on Lantheus in a research note on Monday, May 9th. They set a “buy” rating and a $91.00 target price for the company. StockNews.com assumed coverage on shares of Lantheus in a research note on Thursday, March 31st. They set a “hold” rating for the company. Truist Financial raised their price target on shares of Lantheus from $77.00 to $94.00 in a research note on Monday, May 2nd. Finally, SVB Leerink reaffirmed an “outperform” rating and set a $100.00 price target on shares of Lantheus in a research note on Monday, June 6th.

About Lantheus (Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Recommended Stories

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Want More Great Investing Ideas?

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.